Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all
Enrolling by invitation Not applicable Interventional

Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility

NCT06598345
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Routine Pet Fish Care, Collaborative Communication
Behavioral
Lead sponsor
Duke University
Other
Eligibility
10 Years to 13 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 10:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 14, 2026, 10:21 PM EDT
Not yet recruiting Not applicable Interventional

Argus 2.0 Adoption Study

NCT07425236
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
Interventions
KOS Argus Continuous Glucose Monitoring System
Device
Lead sponsor
KOS Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acceptability of Self-Led Mindfulness-Based Intervention

NCT05115175
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
13 Years to 19 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 14, 2026, 10:21 PM EDT
Terminated Phase 2 Interventional Results available

A Study in Participants With Diabetic Kidney Disease

NCT01113801
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
Interventions
LY2382770, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Not applicable Interventional Results available

Omnipod 5 System Compared to Pump Therapy

NCT05409131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Omnipod 5 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Not applicable Interventional Results available

Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes

NCT01722643
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MAxIM, Usual Care
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pancreatic Islet Transplantation Into the Gastric Submucosa

NCT01571817
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Human Pancreatic Islets
Biological
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 10:21 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 14, 2026, 10:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab in T1DM

NCT05574335
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Siplizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 1 Diabetes

NCT01421147
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2963016, Lantus, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Hollywood, Florida • New Port Richey, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 14, 2026, 10:21 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Low-dose IL-2 in Established T1D - The "PROREG" Study

NCT03243058
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type I Diabetes Mellitus

NCT01454284
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
47
States / cities
Concord, California • Fresno, California • La Mesa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 14, 2026, 10:21 PM EDT
Withdrawn Phase 2 Interventional

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

NCT03794973
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 14, 2026, 10:21 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

NCT05480657
View directory record Official record
Conditions
Brittle Type 1 Diabetes Mellitus
Interventions
AT-1501 IV Infusion, Isolated cadaveric islet cells
Biological
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 14, 2026, 10:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

NCT04678557
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VC-01 Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges

NCT03848767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 14, 2026, 10:21 PM EDT
Completed No phase listed Observational

Collection of Breath and Sweat to Identify Indicators of Hypoglycemia

NCT03600116
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 14, 2026, 10:21 PM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 10:21 PM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 14, 2026, 10:21 PM EDT
Terminated Phase 2 Interventional

B-Lymphocyte Immunotherapy in Islet Transplantation

NCT00468442
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab, Rituximab, Sirolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 14, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Detection Study

NCT02688218
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Aerobic Exercise, Resistance Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 14, 2026, 10:21 PM EDT